Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (468) 468
malaria (287) 287
female (283) 283
index medicus (270) 270
male (239) 239
infectious diseases (221) 221
animals (198) 198
child (181) 181
adult (171) 171
child, preschool (161) 161
gabon (159) 159
immunology (150) 150
adolescent (142) 142
children (130) 130
tropical medicine (127) 127
plasmodium falciparum (126) 126
parasitic diseases (125) 125
infant (119) 119
microbiology (113) 113
parasites (111) 111
research (109) 109
parasitology (105) 105
middle aged (101) 101
infections (99) 99
malaria, falciparum - drug therapy (82) 82
malaria, falciparum - immunology (79) 79
antimalarials - therapeutic use (76) 76
health aspects (76) 76
malaria, falciparum - parasitology (76) 76
plasmodium falciparum - immunology (73) 73
young adult (69) 69
public, environmental & occupational health (67) 67
plasmodium-falciparum (62) 62
pregnancy (61) 61
gabon - epidemiology (59) 59
infection (53) 53
antigens (52) 52
plasmodium falciparum - drug effects (52) 52
treatment outcome (51) 51
africa (49) 49
arctic medicine. tropical medicine (48) 48
prevalence (48) 48
risk factors (48) 48
clinical trials (47) 47
malaria, falciparum - blood (47) 47
medicine (47) 47
medicine, general & internal (47) 47
research article (47) 47
blood (46) 46
epidemiology (46) 46
studies (46) 46
vaccines (46) 46
antibodies (44) 44
antimalarials - administration & dosage (44) 44
infectious and parasitic diseases (44) 44
plasmodium falciparum - genetics (44) 44
aged (43) 43
genotype (43) 43
vector-borne diseases (43) 43
antimalarials (41) 41
cytokines (41) 41
efficacy (41) 41
immunity (41) 41
resistance (40) 40
drug resistance (39) 39
drug therapy (39) 39
medical research (39) 39
abridged index medicus (38) 38
analysis (38) 38
plasmodium falciparum - isolation & purification (38) 38
plasmodium-falciparum malaria (38) 38
cerebral malaria (37) 37
malaria, falciparum - epidemiology (37) 37
drug combinations (36) 36
artesunate (35) 35
infant, newborn (35) 35
care and treatment (34) 34
anemia (33) 33
disease (33) 33
double-blind method (33) 33
pharmacology & pharmacy (33) 33
tropical diseases (33) 33
chloroquine (32) 32
erythrocytes (32) 32
vaccination (32) 32
case-control studies (31) 31
cell biology (31) 31
drug therapy, combination (31) 31
parasitemia (31) 31
immunization (30) 30
protection (30) 30
antigens, protozoan - immunology (29) 29
infants (29) 29
mortality (29) 29
polymerase chain reaction (29) 29
prevention (29) 29
safety (29) 29
antimalarials - adverse effects (28) 28
cohort studies (28) 28
expression (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
by Agnandji, Selidji T and Fernandes, José F and Bache, Emmanuel B and Obiang Mba, Régis M and Brosnahan, Jessica S and Kabwende, Lumeka and Pitzinger, Paul and Staarink, Pieter and Massinga-Loembe, Marguerite and Krähling, Verena and Biedenkopf, Nadine and Fehling, Sarah Katharina and Strecker, Thomas and Clark, David J and Staines, Henry M and Hooper, Jay W and Silvera, Peter and Moorthy, Vasee and Kieny, Marie-Paule and Adegnika, Akim A and Grobusch, Martin P and Becker, Stephan and Ramharter, Michael and Mordmüller, Benjamin and Lell, Bertrand and Krishna, Sanjeev and Kremsner, Peter G and VEBCON Consortium
PLoS medicine, ISSN 1549-1277, 2017, Volume 14, Issue 10, p. e1002402
The rVSVΔG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 107 plaque-forming units (PFU) in a trial in Guinea. This study provides further... 
DOUBLE-BLIND | MEDICINE, GENERAL & INTERNAL | OPEN-LABEL | VIRUS | Immunogenicity, Vaccine | Age Factors | Hemorrhagic Fever, Ebola - prevention & control | Humans | Middle Aged | Vaccination | Male | Virus Shedding | Antibodies, Viral - blood | Ebolavirus - immunology | Young Adult | Gabon | Hemorrhagic Fever, Ebola - diagnosis | Time Factors | Hemorrhagic Fever, Ebola - virology | Adult | Ebola Vaccines - immunology | Female | Hemorrhagic Fever, Ebola - immunology | Child | Ebola Vaccines - administration & dosage | Treatment Outcome | Biomarkers - blood | Injections, Intramuscular | Ebola Vaccines - adverse effects | Adaptive Immunity - drug effects | Adolescent | Antibodies, Neutralizing - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial
by Wressnigg, Nina, PhD and Pöllabauer, Eva-Maria, MD and Aichinger, Gerald, MD and Portsmouth, Daniel, PhD and Löw-Baselli, Alexandra, PhD and Fritsch, Sandor, PhD and Livey, Ian, PhD and Crowe, Brian A, PhD and Schwendinger, Michael, PhD and Brühl, Peter, PhD and Pilz, Andreas, PhD and Dvorak, Thomas, PhD and Singer, Julia, PhD and Firth, Clair, MSc and Luft, Benjamin, Prof and Schmitt, Bernhard, MD and Zeitlinger, Markus, MD and Müller, Markus, Prof and Kollaritsch, Herwig, Prof and Paulke-Korinek, Maria, MD and Esen, Meral, MD and Kremsner, Peter G, Prof and Ehrlich, Hartmut J, MD and Barrett, P Noel, Dr
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 8, pp. 680 - 689
Summary Background Lyme borreliosis is caused by Borrelia burgdorferi sensu stricto in the USA and by several Borrelia species in Europe and Asia, but no human... 
Infectious Disease | INFECTIOUS DISEASES | CLINICAL-TRIAL | CELL EPITOPE | BURGDORFERI | ANTIBODY | ALUMINUM ADJUVANTS | ARTHRITIS | IDENTIFICATION | SURFACE PROTEIN-A | DISEASE VACCINE | SCHEDULES | Lyme Disease Vaccines - adverse effects | Bacterial Outer Membrane Proteins - immunology | Double-Blind Method | Immunoglobulin G - blood | Borrelia burgdorferi - immunology | Humans | Middle Aged | Bacterial Vaccines - adverse effects | Male | Pain - chemically induced | Antigens, Surface - adverse effects | Adjuvants, Immunologic - adverse effects | Bacterial Outer Membrane Proteins - adverse effects | Young Adult | Bacterial Vaccines - immunology | Adult | Female | Lyme Disease Vaccines - immunology | Antigens, Surface - immunology | Headache - chemically induced | Lipoproteins - immunology | Lipoproteins - adverse effects | Lyme disease | Singers | Clinical trials | Product development | Adults | Vaccines | Antigenic determinants
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms
by Ménard, Sandie and Ménard, Didier and Khim, Nimol and Beghain, Johann and Adegnika, Ayola A and Shafiul-Alam, Mohammad and Amodu, Olukemi and Rahim-Awab, Ghulam and Barnadas, Céline and Berry, Antoine and Boum, Yap and Bustos, Maria D and Cao, Jun and Chen, Jun-Hu and Collet, Louis and Cui, Liwang and Thakur, Garib-Das and Dieye, Alioune and Djallé, Djibrine and Dorkenoo, Monique A and Eboumbou-Moukoko, Carole E and Espino, Fe-Esperanza-Caridad J and Fandeur, Thierry and Ferreira-da-Cruz, Maria-Fatima and Fola, Abebe A and Fuehrer, Hans-Peter and Hassan, Abdillahi M and Herrera, Socrates and Hongvanthong, Bouasy and Houzé, Sandrine and Ibrahim, Maman L and Jahirul-Karim, Mohammad and Jiang, Lubin and Kano, Shigeyuki and Ali-Khan, Wasif and Khanthavong, Maniphone and Kremsner, Peter G and Lacerda, Marcus and Leang, Rithea and Leelawong, Mindy and Li, Mei and Lin, Khin and Mazarati, Jean-Baptiste and Morlais, Isabelle and Muhindo-Mavoko, Hypolite and Musset, Lise and Na-Bangchang, Kesara and Nambozi, Michael and Niaré, Karamoko and Noedl, Harald and Ouédraogo, Jean-Bosco and Pillai, Dylan R and Pradines, Bruno and Quang-Phuc, Bui and Ramharter, Michael and Randrianarivelojosia, Milijaona and Sattabongkot, Jetsumon and Sheikh-Omar, Abdiqani and Silué, Kigbafori D and Sirima, Sodiomon B and Sutherland, Colin and Syafruddin, Din and Tahar, Rachida and Tang, Lin-Hua and Touré, Offianan A and Tshibangu-wa-Tshibangu, Patrick and Vigan-Womas, Inès and Warsame, Marian and Wini, Lyndes and Zakeri, Sedigheh and Kim, Saorin and Eam, Rotha and Berne, Laura and Khean, Chanra and Chy, Sophy and Ken, Malen and Loch, Kaknika and Canier, Lydie and Duru, Valentine and Legrand, Eric and Barale, Jean-Christophe and Stokes, Barbara and Straimer, Judith and Witkowski, Benoit and Fidock, David A and Rogier, Christophe and Ringwald, Pascal and Ariey, Frederic and Mercereau-Puijalon, Odile and KARMA Consortium
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 25, pp. 2453 - 2464
The emergence of Plasmodium falciparum resistance to artemisinin-based therapy is a major global health challenge. In this report, investigators describe the... 
CLEARANCE | MEDICINE, GENERAL & INTERNAL | IN-VITRO | WESTERN CAMBODIA | SUB-SAHARAN AFRICA | ARTEMISININ RESISTANCE MUTATIONS | MALARIA | CHINA-MYANMAR BORDER | K13 PROPELLER GENE | MOLECULAR MARKER | DRUG-RESISTANCE | Malaria, Falciparum - drug therapy | Humans | Genotype | Plasmodium falciparum - drug effects | Protozoan Proteins - genetics | Sequence Analysis, DNA | Lactones - pharmacology | Lactones - therapeutic use | Polymorphism, Genetic | Asia, Southeastern | Endemic Diseases | Drug Resistance - genetics | Malaria, Falciparum - parasitology | Artemisinins - pharmacology | Algorithms | Artemisinins - therapeutic use | China | Plasmodium falciparum - genetics | Mutation | Malaria | Artemisinin | Alleles | Parasites | Drug resistance | Polymorphism | Malaria, Falciparum | Parasitology | Protozoan Proteins | Lactones | Life Sciences | Plasmodium falciparum | Microbiology and Parasitology | Artemisinins | Drug Resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
by Agnandji, Selidji T and Huttner, Angela and Zinser, Madeleine E and Njuguna, Patricia and Dahlke, Christine and Fernandes, José F and Yerly, Sabine and Dayer, Julie-Anne and Kraehling, Verena and Kasonta, Rahel and Adegnika, Akim A and Altfeld, Marcus and Auderset, Floriane and Bache, Emmanuel B and Biedenkopf, Nadine and Borregaard, Saskia and Brosnahan, Jessica S and Burrow, Rebekah and Combescure, Christophe and Desmeules, Jules and Eickmann, Markus and Fehling, Sarah K and Finckh, Axel and Goncalves, Ana Rita and Grobusch, Martin P and Hooper, Jay and Jambrecina, Alen and Kabwende, Anita L and Kaya, Gürkan and Kimani, Domtila and Lell, Bertrand and Lemaître, Barbara and Lohse, Ansgar W and Massinga-Loembe, Marguerite and Matthey, Alain and Mordmüller, Benjamin and Nolting, Anne and Ogwang, Caroline and Ramharter, Michael and Schmidt-Chanasit, Jonas and Schmiedel, Stefan and Silvera, Peter and Stahl, Felix R and Staines, Henry M and Strecker, Thomas and Stubbe, Hans C and Tsofa, Benjamin and Zaki, Sherif and Fast, Patricia and Moorthy, Vasee and Kaiser, Laurent and Krishna, Sanjeev and Becker, Stephan and Kieny, Marie-Paule and Bejon, Philip and Kremsner, Peter G and Addo, Marylyn M and Siegrist, Claire-Anne
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1647 - 1660
In this set of four phase 1 studies, a recombinant vesicular stomatitis virus (rVSV)–based Ebola vaccine induced Ebola virus–specific immune responses and was... 
IMMUNITY | MEDICINE, GENERAL & INTERNAL | MARBURG VIRUS | PROTECTS NONHUMAN-PRIMATES | VSV | INFECTION | VESICULAR STOMATITIS-VIRUS | Double-Blind Method | Hemorrhagic Fever, Ebola - prevention & control | Viremia | Humans | Middle Aged | Ebola Vaccines - administration & dosage | Male | Virus Shedding | Recombinant Proteins | Antibodies, Viral - blood | Ebola Vaccines - adverse effects | Ebolavirus - immunology | Ebolavirus - isolation & purification | Exanthema - etiology | Dermatitis - etiology | Vesiculovirus | Arthritis - etiology | Adult | Ebola Vaccines - immunology | Female | Viral Envelope Proteins - immunology | Hemorrhagic Fever, Ebola - immunology | Membrane Glycoproteins - immunology | Ebola virus | Clinical trials | Ebola virus infections | Care and treatment | Usage | Research | Urine | Immunization | Arthritis | Vaccines | Joint diseases | Fever | Studies | Stomatitis | Pain | Immunogenicity | Replication | Skin | Safety | Saliva | Public health | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Sterile protection against human malaria by chemoattenuated PfSPZ vaccine
by Mordmüller, Benjamin and Surat, Güzin and Lagler, Heimo and Chakravarty, Sumana and Ishizuka, Andrew S and Lalremruata, Albert and Gmeiner, Markus and Campo, Joseph J and Esen, Meral and Ruben, Adam J and Held, Jana and Calle, Carlos Lamsfus and Mengue, Juliana B and Gebru, Tamirat and Ibáñez, Javier and Sulyok, Mihály and James, Eric R and Billingsley, Peter F and Natasha, Kc and Manoj, Anita and Murshedkar, Tooba and Gunasekera, Anusha and Eappen, Abraham G and Li, Tao and Stafford, Richard E and Li, Minglin and Felgner, Phil L and Seder, Robert A and Richie, Thomas L and Sim, B. Kim Lee and Hoffman, Stephen L and Kremsner, Peter G
Nature, ISSN 0028-0836, 02/2017, Volume 542, Issue 7642, pp. 445 - 449
A highly protective malaria vaccine would greatly facilitate the prevention and elimination of malaria and containment of drug-resistant parasites(1). A high... 
DIRECT VENOUS INOCULATION | ANTIBODIES | LIVER-STAGE | IMMUNIZATION | IMMUNITY | CD8+ T-CELLS | MULTIDISCIPLINARY SCIENCES | PLASMODIUM-FALCIPARUM SPOROZOITES | CHLOROQUINE PROPHYLAXIS | INFECTION | HUMAN VOLUNTEERS | Malaria, Falciparum - prevention & control | Double-Blind Method | Antibodies, Protozoan - immunology | Humans | Middle Aged | Chloroquine - therapeutic use | Plasmodium falciparum - immunology | Healthy Volunteers | Sporozoites - immunology | Young Adult | Malaria, Falciparum - blood | Malaria, Falciparum - parasitology | Antibodies, Protozoan - blood | Vaccines, Attenuated - immunology | Malaria Vaccines - administration & dosage | Plasmodium falciparum - classification | Time Factors | Vaccines, Attenuated - administration & dosage | Adolescent | Malaria Vaccines - immunology | Malaria, Falciparum - immunology | Adult | T-Lymphocytes - immunology | Immunologic Memory - immunology | Prevention | Dosage and administration | Malaria | Malaria vaccine | Proteins | Automation | Immunoglobulins | Mosquitoes | Lymphocytes | Liver | Infections | Parasites | Vaccines | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children
by Sirima, Sodiomon B and Mordmüller, Benjamin and Milligan, Paul and Ngoa, Ulysse Ateba and Kironde, Fred and Atuguba, Frank and Tiono, Alfred B and Issifou, Saadou and Kaddumukasa, Mark and Bangre, Oscar and Flach, Clare and Christiansen, Michael and Bang, Peter and Chilengi, Roma and Jepsen, Søren and Kremsner, Peter G and Theisen, Michael and The GMZ2 Trial Study Group and GMZ2 Trial Study Grp and GMZ2 Trial Study Group
Vaccine, ISSN 0264-410X, 2016, Volume 34, Issue 38, pp. 4536 - 4542
Highlights • The GMZ2 fusion protein consist of the non-repeat region of falciparum GLURP genetically fused to a msp3 fragment. • The GMZ2 fusion protein... 
Allergy and Immunology | Plasmodium falciparum | GLURP | Phase 2 clinical trial | Antibody | Efficacy | Vaccine | MSP3 | GMZ2 | ANTIBODIES | MEDICINE, RESEARCH & EXPERIMENTAL | IMMUNITY | PROTECTION | SAFETY | IMMUNOLOGY | SUBUNIT VACCINE | RTS,S/AS01 | INDIVIDUALS | CANDIDATE GMZ2 | IMMUNOGENICITY | GLUTAMATE-RICH PROTEIN | Recombinant Fusion Proteins - immunology | Malaria, Falciparum - prevention & control | Adjuvants, Immunologic - administration & dosage | Antigens, Protozoan - immunology | Immunoglobulin G - blood | Humans | Child, Preschool | Infant | Male | Aluminum Hydroxide - administration & dosage | Ghana | Gabon | Antibodies, Protozoan - blood | Burkina Faso | Malaria Vaccines - immunology | Female | Uganda | Protozoan Proteins - immunology | Clinical trials | Vaccines | Malaria | Analysis | Malaria vaccine | Vaccination | Proteins | Antigens | Immunoglobulins | Parasites | Age | Blood | Fever | Tropical diseases | Children & youth
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
by Neafsey, Daniel E and Juraska, Michal and Bedford, Trevor and Benkeser, David and Valim, Clarissa and Griggs, Allison and Lievens, Marc and Abdulla, Salim and Adjei, Samuel and Agbenyega, Tsiri and Agnandji, Selidji T and Aide, Pedro and Anderson, Scott and Ansong, Daniel and Aponte, John J and Asante, Kwaku Poku and Bejon, Philip and Birkett, Ashley J and Bruls, Myriam and Connolly, Kristen M and D’Alessandro, Umberto and Dobaño, Carlota and Gesase, Samwel and Greenwood, Brian and Grimsby, Jonna and Tinto, Halidou and Hamel, Mary J and Hoffman, Irving and Kamthunzi, Portia and Kariuki, Simon and Kremsner, Peter G and Leach, Amanda and Lell, Bertrand and Lennon, Niall J and Lusingu, John and Marsh, Kevin and Martinson, Francis and Molel, Jackson T and Moss, Eli L and Njuguna, Patricia and Ockenhouse, Christian F and Ogutu, Bernhards Ragama and Otieno, Lucas and Otieno, Walter and Otieno, Kephas and Owusu-Agyei, Seth and Park, Daniel J and Pellé, Karell and Robbins, Dana and Russ, Carsten and Ryan, Elizabeth M and Sacarlal, Jahit and Sogoloff, Brian and Sorgho, Hermann and Tanner, Marcel and Theander, Thor and Valea, Innocent and Volkman, Sarah K and Yu, Qing and Lapierre, Didier and Birren, Bruce W and Gilbert, Peter B and Wirth, Dyann F
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 21, pp. 2025 - 2037
There is a tremendous need for a malaria vaccine. By means of a sieve analysis, the RTS,S/AS01 candidate vaccine, which is in advanced clinical development,... 
MEDICINE, GENERAL & INTERNAL | IMMUNOGENICITY | SAFETY | PLASMODIUM-FALCIPARUM INFECTION | CIRCUMSPOROZOITE PROTEIN | RTS,S/AS02A | DOUBLE-BLIND | EXPANDED-PROGRAM | ENDEMIC AREA | SELECTION | CHILDREN | Genetic Variation | Malaria, Falciparum - parasitology | Malaria, Falciparum - prevention & control | Humans | Plasmodium falciparum - genetics | Africa | Malaria Vaccines - immunology | Malaria, Falciparum - immunology | Female | Infant | Male | Treatment Outcome | Care and treatment | Usage | Malaria | Antimalarials | Clinical trials | Dosage and administration | Children | Health aspects | Antigens | Vaccination | Amino acids | Protein C | Infants | Genetic diversity | Vaccines | Parasites | Population genetics | Polymerase chain reaction | Proteins | Alleles | Circumsporozoite protein | DNA sequencing
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety and immunogenicity of rVSV[DELTA]G-ZEBOV-GP Ebola vaccine in adults and children in Lambar?n?, Gabon: A phase I randomised trial
by Agnandji, Selidji T and Fernandes, Jos? F and Bache, Emmanuel B and Obiang Mba, R?gis M and Brosnahan, Jessica S and Kabwende, Lumeka and Pitzinger, Paul and Staarink, Pieter and Massinga-Loembe, Marguerite and Kr?hling, Verena and Biedenkopf, Nadine and Fehling, Sarah Katharina and Strecker, Thomas and Clark, David J and Staines, Henry M and Hooper, Jay W and Silvera, Peter and Moorthy, Vasee and Kieny, Marie-Paule and Adegnika, Akim A and Grobusch, Martin P and Becker, Stephan and Ramharter, Michael and Mordm?ller, Benjamin and Lell, Bertrand and Krishna, Sanjeev and Kremsner, Peter G
PLoS Medicine, ISSN 1549-1277, 10/2017, Volume 14, Issue 10
Background The rVSV[DELTA]G-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 x 10.sup.7 plaque-forming units (PFU) in a trial in Guinea. This... 
Ebola virus | Virus diseases | Medical research | Vaccination | Clinical trials | Medicine, Experimental | Ebola virus infections | Product development | Vaccines
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
by Huttner, Angela and Agnandji, Selidji Todagbe and Combescure, Christophe and Fernandes, José F and Bache, Emmanuel Bache and Kabwende, Lumeka and Ndungu, Francis Maina and Brosnahan, Jessica and Monath, Thomas P and Lemaître, Barbara and Grillet, Stéphane and Botto, Miriam and Engler, Olivier and Portmann, Jasmine and Siegrist, Denise and Bejon, Philip and Silvera, Peter and Kremsner, Peter and Siegrist, Claire-Anne and KRISHNA, Sanjeev and ADDO, Marylyn M and BECKER, Stephan and KRÄHLING, Verena and NJUGUNA, Patricia and KIENY, Marie-Paule and AHMED, Rafi and ANDERSON, Jenna and AUDERSET, Floriane and BORGIANNI, Luisa and CIABATTINI, Annalisa and HAKS, Marielle C and HARANDI, Ali and HEPPNER, Donald Gray and GERLINI, Alice and MEDAGLINI, Donata and OTTENHOFF, Tom H.M and PEJOSKI, David and PAGE, Mark and POZZI, Gianni and SANTORO, Francesco and DUBEY, Sheri and FERNANDES, José F and NAKAYA, Helder and OROURKE, Fiona and ROTHENBERGER, Sylvia and VSV-EBOVAC and VSV-EBOPLUS Consortia and VEBCON and VEBCON VSV-EBOVAC VSV-EBOPLUS
The Lancet Infectious Diseases, ISSN 1473-3099, 07/2018, Volume 18, Issue 7, pp. 738 - 748
The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following... 
NONHUMAN-PRIMATES | TRIAL | IMMUNITY | INFECTIOUS DISEASES | HEALTHY-ADULTS | IMMUNOGENICITY | SAFETY | DOUBLE-BLIND | CANDIDATE | VACCINES | Humans | Middle Aged | Ebola Vaccines - therapeutic use | Male | Kenya | Antibodies, Viral - blood | Switzerland | Dose-Response Relationship, Drug | Ebolavirus - drug effects | Medication Adherence | Adult | Ebola Vaccines - immunology | Female | Hemorrhagic Fever, Ebola - drug therapy | Cohort Studies | Ebola virus | Virus diseases | Medical research | Analysis | Vaccination | Medicine, Experimental | Ebola virus infections | Immunization | Immunoglobulins | Immunoglobulin G | Glycoprotein | Viral diseases | Clinical trials | Antibodies | Viruses | Glycoproteins | Arthritis | Vaccines | Immunity | Studies | Stomatitis | Infectious diseases | Enzyme-linked immunosorbent assay | Recombinant
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Intermittent Preventive Treatment against Malaria in Infants in Gabon: A Randomized, Double-Blind, Placebo-Controlled Trial
by Martin P. Grobusch and Bertrand Lell and Norbert G. Schwarz and Julian Gabor and Jenny Dörnemann and Marc Pötschke and Sunny Oyakhirome and Georg C. Kiessling and Magdalena Necek and Matthias U. Längin and Peter Klein Klouwenberg and Anna Klöpfer and Benjamin Naumann and Handan Altun and Selidji T. Agnandji and Julia Goesch and Marieluise Decker and Carmen L. Ospina Salazar and Christian Supan and Davy U. Kombila and Lea Borchert and Kai B. Köster and Peter Pongratz and Akim A. Adegnika and Isabelle von Glasenapp and Saadou Issifou and Peter G. Kremsner
The Journal of Infectious Diseases, ISSN 0022-1899, 12/2007, Volume 196, Issue 11, pp. 1595 - 1602
Background. Intermittent preventive treatment aims to maximize the protective effects of malaria chemoprophylaxis while minimizing the deleterious effects.... 
Health care administration | Malaria | Medication administration | Anemia | Placebos | Antimalarials | Infants | Children | Parasites | Dosage | Hemoglobins | INFECTIOUS DISEASES | QUALITY | SULFADOXINE-PYRIMETHAMINE TREATMENT | UNCOMPLICATED FALCIPARUM-MALARIA | AMODIAQUINE | TANZANIAN INFANTS | MICROBIOLOGY | IMMUNOLOGY | PREGNANCY | AFRICAN CHILDREN | ROUTINE VACCINATIONS | ANEMIA | ARTESUNATE | Malaria, Falciparum - prevention & control | Anemia - epidemiology | Humans | Hematocrit | Sulfadoxine - administration & dosage | Infant | Male | Sulfadoxine - adverse effects | Incidence | Patient Selection | Malaria, Falciparum - blood | Pyrimethamine - administration & dosage | Gabon - epidemiology | Malaria, Falciparum - epidemiology | Female | Parasitemia - epidemiology | Antimalarials - adverse effects | Double-Blind Method | Drug Administration Schedule | Pyrimethamine - adverse effects | Kaplan-Meier Estimate | Anemia - chemically induced | Hemoglobins - metabolism | Treatment Outcome | Parasitemia - blood | Antimalarials - administration & dosage | Parasitemia - prevention & control | Parasitemia - parasitology | Research Design | Drug Combinations | Prevention | Demographic aspects | Experimental design | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Nitric Oxide Synthase 2Lambaréné (G-954C), Increased Nitric Oxide Production, and Protection against Malaria
by Kun, Jürgen F.  and Mordmüller, Benjamin  and Perkins, Douglas J.  and May, Jürgen  and Mercereau-Puijalon, Odile  and Alpers, Michael  and Weinberg, J. Brice  and Kremsner, Peter G. 
The Journal of Infectious Diseases, ISSN 0022-1899, 8/2001, Volume 184, Issue 3, pp. 330 - 336
A point mutation in the promoter of the nitric oxide synthase 2 gene (NOS2), termed NOS2Lambaréné (NOS2-G954C), protects heterozygous carriers against severe... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights